SHORT COMMUNICATION
973
Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and
Extracorporeal Photopheresis
Valeria BEHLE 1 , Tanja VON BRAUNMÜHL 2 , Cyrus SAYEHLI 3 , Anja GESIERICH 1 , Matthias GOEBELER 1 , Eva GEISSINGER 4
and Marion WOBSER 1
Department of Dermatology, Venereology and Allergology, University Hospital Wuerzburg, Josef-Schneider-Straße 2, DE-97080 Wuerzburg,
Department of Dermatology, University Hospital Munich and Municipal Hospital of Munich, Munich, 3 Department of Internal Medicine, Early
Clinical Trial Unit, University Hospital Wuerzburg, and 4 Institute of Pathology, Comprehensive Cancer Center Mainfranken, University of
Wuerzburg, Wuerzburg, Germany. E-mail: [email protected]
1
2
Despite recent advances in basic and translational
research in the field of cutaneous lymphomas (1, 2), ef-
fective treatment options for advanced mycosis fungoides
(MF) and Sézary syndrome (SS) are limited. Conventio-
nal therapies usually result only in short-lived remission
(3), lacking any long-term advantage of more aggres-
sive chemotherapeutic regimens (4) and having septic
complications. A recent retrospective meta-analysis
found that immunological treatment approaches, such
as interferon or extracorporeal photopheresis, as well
as epigenetic modifiers, produce better rates of disease
control in patients with MF and SS than does immuno-
suppressive chemotherapy (5). Hence, better immunomo-
dulating drugs addressing the tumour microenvironment
of cutaneous lymphomas (6) as well as novel targeted
therapies and innovative combinational approaches (7)
are urgently required (8).
We report here a patient with SS and nodal CD30-
positive manifestation who was treated with a combina-
tion of extracorporeal photopheresis (ECP) and the drug-
conjugated anti-CD30 antibody brentuxi